XML 62 R33.htm IDEA: XBRL DOCUMENT v3.20.4
REVENUE REVENUE (Tables)
 12 Months Ended
Dec. 31, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue [Table Text Block]
The following table summarizes the disaggregation of revenue by nature:
 Year Ended December 31,
Dollars in Millions202020192018
Net product sales$41,321 $25,174 $21,581 
Alliance revenues615 597 647 
Other revenues582 374 333 
Total Revenues$42,518 $26,145 $22,561 
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]
 Year Ended December 31,
 202020192018
McKesson Corporation31 %26 %25 %
AmerisourceBergen Corporation25 %20 %20 %
Cardinal Health, Inc.19 %17 %17 %
Reconciliation of Gross Product Sales to Net Product Sales [Table Text Block]
The following table summarizes GTN adjustments:
 Year Ended December 31,
Dollars in Millions202020192018
Gross product sales$60,016 $37,206 $30,174 
GTN adjustments(a)
Charge-backs and cash discounts(5,827)(3,675)(2,735)
Medicaid and Medicare rebates(7,595)(4,941)(3,225)
Other rebates, returns, discounts and adjustments(5,273)(3,416)(2,633)
Total GTN adjustments(18,695)(12,032)(8,593)
Net product sales$41,321 $25,174 $21,581 
(a)    Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $106 million in 2020, $132 million in 2019 and $96 million in 2018.
Revenue from External Customers by Products and Services [Table Text Block]
The following table summarizes the disaggregation of revenue by product and region:
 Year Ended December 31,
Dollars in Millions202020192018
Prioritized Brands
Revlimid$12,106 $1,299 $— 
Eliquis9,168 7,929 6,438 
Opdivo6,992 7,204 6,735 
Orencia3,157 2,977 2,710 
Pomalyst/Imnovid3,070 322 — 
Sprycel2,140 2,110 2,000 
Yervoy1,682 1,489 1,330 
Abraxane1,247 166 — 
Empliciti381 357 247 
Reblozyl274 — — 
Inrebic55 5 — 
Onureg17 — — 
Zeposia12 — — 
Established Brands
Vidaza455 58 — 
Baraclude447 555 744 
Other Brands(a)
1,315 1,674 2,357 
Total Revenues$42,518 $26,145 $22,561 
United States$26,577 $15,342 $12,586 
Europe9,853 6,266 5,658 
Rest of World5,457 4,013 3,733 
Other(b)
631 524 584 
Total Revenues$42,518 $26,145 $22,561 
(a)    Includes BMS and Celgene products in 2020 and 2019.
(b)    Other revenues include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.